Table 1.

Baseline characteristics according to fibroblast growth factor 23 quartiles in the HALT-PKD Study A

CharacteristicTotal, n=540FGF23 Quartiles, pg/mlP Value
Quartile 1 ≤33.3Quartile 2 =33.3–43.6Quartile 3 =43.6–55.9Quartile 4 >55.9
Age, yr, mean±SD37±836±937±836±837±80.54
Men, n (%)273 (51)48 (36)63 (47)77 (57)85 (63)<0.001
White, n (%)500 (93)122 (91)125 (93)130 (96)123 (92)0.51
Systolic BP, mmHg, mean±SD127±14124±13128±15125±14130±130.02
Body mass index, kg/m2, mean±SD27±525±527±628±528±5<0.001
eGFR, ml/min per 1.73 m2, mean±SD91±1798±1692±1789±1787±17<0.001
Calcium, mg/dl, mean±SD9.4±0.49.3±0.49.4±0.49.4±0.49.4±0.40.22
Phosphate, mg/dl, mean±SD3.4±0.53.3±0.53.4±0.63.4±0.53.4±0.60.47
Urine albumin, mg/24 h, median (IQR)18 (12–33)16 (11–30)20 (13–33)18 (12–31)20 (13–32)0.41
Height-adjusted total kidney volume, ml/m, median (IQR)589 (405–860)513 (350–696)565 (399–794)623 (441–980)693 (459–1004)0.002
PKD genotype 0, n (%)45 (9)9 (7)13 (10)14 (11)9 (7)0.57
PKD genotype 1, n (%)369 (74)87 (71)93 (73)90 (73)99 (79)
PKD genotype 2, n (%)83 (17)26 (21)21 (17)19 (16)17 (14)
  • Values are expressed as means±SD unless otherwise specified. FGF23, fibroblast growth factor 23; IQR, interquartile range. PKD, polycystic kidney disease.